Evidence map›Paper›PMID 41644523›Full record

ArticleNature communications2026

Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression.

Vincent Cuminetti, Emeline Boet, Marcel Heugel, Joanna Konieczny, Aurora Bernal, Manuel J Gomez, Franco Grimolizzi, Nuria Vilaplana-Lopera, Marc Ferré, Alicia Villatoro and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Vincent CuminettiStem Cells, Ageing and Cancer Research Group, Centre for Embryology and Healthy Development, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0001-8396-710X
Emeline BoetCentre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, Toulouse, France.
Marcel Heugel *Stem Cells, Ageing and Cancer Research Group, Centre for Embryology and Healthy Development, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Joanna Konieczny *Stem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, MH2 building level 10, UiT - The Arctic University of Norway, Tromsø, Norway.ORCID 0000-0002-4267-6012
Aurora BernalStem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, MH2 building level 10, UiT - The Arctic University of Norway, Tromsø, Norway.ORCID 0000-0002-5741-7865
Manuel J GomezBioinformatics Unit, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Franco GrimolizziStem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, MH2 building level 10, UiT - The Arctic University of Norway, Tromsø, Norway.
Nuria Vilaplana-LoperaInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0002-3156-9908
Marc FerréStem Cells, Ageing and Cancer Research Group, Centre for Embryology and Healthy Development, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Alicia VillatoroStem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, MH2 building level 10, UiT - The Arctic University of Norway, Tromsø, Norway.
Deo P PandeyTargeting tumors of central nervous system Project Group, Centre of Embryology and Healthy Development, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Carlos TorrojaBioinformatics Unit, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0001-8914-3400
Hagar TamanGenomics Support Centre Tromsø, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH building level 9, Tromsø, Norway.
Ruth H PaulssenGenomics Support Centre Tromsø, Faculty of Health Sciences, UiT - The Arctic University of Norway, MH building level 9, Tromsø, Norway.ORCID 0000-0001-6436-4143
Thomas VoglInstitute of Immunology, University of Münster, Münster, Germany.ORCID 0000-0001-9669-7479
Caroline A HeckmanInstitute for Molecular Medicine Finland, FIMM, Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-4324-8706
Anders VikDepartment of Hematology, University Hospital of North Norway, Tromsø, Norway.
Giovanna GiovinazzoPluripotent Cell Technology Unit, CNIC, Madrid, Spain.ORCID 0000-0002-5391-0441
Nick van Gastelde Duve Institute, Catholic University of Louvain, Brussels, Belgium.ORCID 0000-0002-0563-3590
Paloma GarcíaInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0001-5582-8575
Fátima Sánchez-CaboBioinformatics Unit, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0003-1881-1664
Jean-Emmanuel SarryCentre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, Toulouse, France.ORCID 0000-0002-6704-2032
Lorena ArranzStem Cells, Ageing and Cancer Research Group, Centre for Embryology and Healthy Development, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. lorena.arranz@medisin.uio.no.ORCID 0000-0002-5896-4238

Funding

Kreftforeningen (Norwegian Cancer Society) 6765150Norges Forskningsråd (Research Council of Norway) 247596Norges Forskningsråd (Research Council of Norway) 250901Norges Forskningsråd (Research Council of Norway) 332713
6 · The paper itself

Abstract

Despite intriguing roles for the Succinate receptor (Sucnr1) in inflammation, few studies have explored its role in hematopoiesis. Here, we show that low SUCNR1 represents a marker for reduced overall and progression-free survival in acute myeloid leukemia (AML) patients. Succinic acid, which displays Sucnr1-dependent and independent effects, promotes disease in mouse models of pre-leukemic myelopoiesis, AML and AML xenografts, expressing low SUCNR1. In vivo global or hematopoietic deletion of Sucnr1 induces expansion of hematopoietic stem and progenitor cells (HSPC) and hematopoiesis, whilst Sucnr1-tomato

Indexed as

HematopoiesisLeukemia, Myeloid, AcuteReceptors, G-Protein-CoupledAnimalsCalgranulin ACalgranulin BDisease ProgressionFemaleHematopoietic Stem CellsHumansMaleMiceMice, KnockoutSuccinic AcidCalgranulin ACalgranulin BReceptors, G-Protein-CoupledSuccinic Acid

Identifiers

PMID41644523
PMCPMC12982520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.